Académique Documents
Professionnel Documents
Culture Documents
Abstract
Introduction
There have been claims that cannabis and its derivative compounds have medicinal use including use for diabetes. However,
cannabis (with some limited exceptions discussed below) has
no current status as a medicine since it became illegal in the
UK under the Dangerous Drugs Act 1925. Cannabis is now
1
THE
The
BRITISH
Author(s),
JOURNAL
2010. Reprints
OF DIABETES
and permissions:
AND VASCULAR
http://www.sagepub.co.uk/journalsPermissions.nav
DISEASE
10.1177/1474651410385860
267
REVIEW
have up to 20% (skunk refers to a range of stronger types of cannabis, grown either under artificial lights or in a greenhouse, often
using hydroponic techniques).4 Despite concerns about increased
potency, the evidence is mixed, with recent studies indicating
broadly similar ranges of potency over the last 10 years.7
The only cannabinoids available as medicines in the UK are
nabilone (a synthetic cannabinoid) and Sativex (cannabis plant
extract containing THC and CBD) but neither are licensed for use
in diabetes. Nabilone is licensed for nausea and vomiting caused
by cytotoxic chemotherapy that is unresponsive to conventional
antiemetics, while Sativex was granted a product licence in June
2010 as an add-on treatment for symptom improvement in
multiple sclerosis patients with moderate to severe spasticity.8
Rimonabant (an inverse agonist for the cannabinoid receptor
CB19), which had been licensed as an appetite suppressant, was
withdrawn from the market in 2009 over concerns about psychiatric side effects (particularly depression and suicidal ideation).10
Diabetes
Prevalence (%) of cannabis
Prevalence (%) of
diagnosed diabetes
200820091
in England, 200616
Ageband
Ageband
1619
18.3
1624
0.8
2024
19.1
2534
1.2
2529
12.1
3544
1.8
3034
8.2
4554
4.8
3544
4.6
5564
7.2
4554
2.4
6574
12.9
5559
1.1
75+
11.7
Sex
Sex
Men
10.6
Men
5.6
Women
5.2
Women
4.2
Cannabis
8.0
6.0
4.0
2.0
0.0
1993
1994
1998
2003
2006
268
REVIEW
at all) by citing experimental animal studies that used CBD (usually only present in small quantities in herbal cannabis). Such
animal studies, for example those by Weiss and colleagues,27
make no such claims for cannabis.
The evidence for whether herbal cannabis has beneficial or
adverse effects in diabetes remains inconclusive. Various websites make anecdotal reports about cannabis having beneficial
effects, such as stabilising or lowering blood sugar.28,29 Some also
report adverse effects, such as Stark,25 who comments that
cannabis may cause decreased judgement and increased appetite, but offers no additional information about these effects
(e.g. whether judgement includes awareness of impending
hypoglycaemia).25 However, physiological and pharmacological
studies do not provide unequivocal support for anecdotal reports
and claims of benefit of herbal cannabis in diabetes; rather, if
anything, they point to the situation being highly complex.
THC, the major active component of herbal cannabis, appears
to principally exert its pharmacological action by stimulating the
endocannabinoid system, via the cannabinoid cell-surface receptors CB1 and CB2. This system appears to have a role in the
regulation of body weight and food intake, and the development
of hyperglycaemia, insulin resistance and dyslipidaemia.30-33
In various experimental models THC was shown to interfere
with both the action of insulin and its release. In type 2 diabetes the glucose uptake of cells is impaired due to insulin resistance. THC can increase insulin-induced glucose uptake, as
demonstrated in a study in cultured adipocytes.34 It was also
shown that TNFa affects the effectiveness of insulin on glucose
uptake by interfering with insulin signalling,35 and the expression of GLUT4 in adipocytes.36 THC has been demonstrated to
decrease the level of TNFa in various experimental models.30,37
Studies have also demonstrated the increased gene expression
of IRS-1, IRS-2 and GLUT4 by THC, suggesting that this compound exhibits an insulin-sensitising effect.30 Endocannabinoid
receptors (CB1 and CB2 receptors as well as other yet unclassified receptors) stimulate intracellular calcium transients [Ca2+]i
leading to the release of insulin.38 In a study using RINm5F rat
insulinoma -cells, it was shown that CB1 and CB2 receptor
agonists stimulate insulin secretion via the phosphatidyl inositol
phospholipase-C pathway and the mobilisation of [Ca2+]i
through IP3 receptors.39 Furthermore, THC stimulated the
release of insulin from rat pancreatic islet cells by increasing the
activity of lipooxygenase and by accelerating the metabolism of
arachidonic acid. Inhibition of lipooxygenase (with inhibitor
3-amino-1-(3-trifluoromethylphenyl)-2-pyrazoline hydrochloride) inhibited insulin release in cells exposed to either glucose
or THC.40 THC was also shown to affect the expression of betatype TGF (TGF-b1, b2 and b3) as well as the expression of IGF-I
in mice.41 It is also likely that THC enhances insulin action.
Although these data suggest that cannabis could impact on
glucose metabolism and the diabetic patient by simultaneously
increasing the expression and release of insulin from the pancreatic b-cells and also by sensitising the peripheral tissues to
enhance glucose uptake, the supporting evidence is based on
studies carried out in cultured cells and not in diabetic patients.
269
REVIEW
Clinical effect
Cannabinoid
Rimonabant
endocannabinoid overactivity)
Evidence
Rimonabant
endocannabinoid overactivity)
Insufficiently understood
Key: BMI = body mass index; BP = blood pressure; CBD = cannabidiol; DPN = diabetic peripheral neuropathy; HbA1C = glycosylated haemoglobin;
RCT = randomised controlled trial; RIO-Diabetes = Rimonabant in type 2 diabetes; RIO-Europe = Rimonabant In Obesity Europe;
THC = 9-tetrahydrocannabinol
270
REVIEW
In short, there is mounting evidence pointing to dysfunction of the endocannabinoid system having an important role
in the development of type 2 diabetes and obesity.29 However,
effectively targeting this system to treat or prevent type 2 diabetes appears to be far more likely with individual cannabinoids
than herbal cannabis. This equally appears to be the case with
cannabinoids being used in the treatment and prevention of
the complications of diabetes, as this review will now consider.
Neuropathy
Neuropathy is a commonly encountered complication of diabetes and can manifest in any of the body systems, resulting in
numbness, pain and weakness. Protection against oxidative
stress has been implicated as being important in reducing neuropathy in experimental settings. In STZ-induced diabetic rats,
C. sativa extract increased the level of reduced glutathione in the
liver, resulting in a significant reduction in liver lipid peroxidation,
in addition to relieving mechanical allodynia, when administered
repeatedly.56 In direct contrast to these findings, a double-blind
clinical trial of Sativex (which contains THC and CBD) found no
difference in the ability of the cannabis-based product to relieve
neuropathic pain when compared with placebo.57 Of note were
the observations that depression influenced the baseline pain
scores and that patients showed improvement of symptoms
regardless of the treatment regimen, which demonstrates the
strong association of depression with pain perception.
Retinopathy
Retinopathy in diabetic patients is the leading cause of preventable blindness in people of working age and is associated with
an increased risk of other vascular complications including
coronary heart disease and stroke.58 Research in rat models of
diabetes has demonstrated that the cannabinoid CBD exerts
protection against damage to the bloodbrain barrier during
the initial stages of diabetes. This protection appears to be
linked to a reduction in expression of inflammatory and adhesion molecules including TNF and ICAM-1, among others,59,60
in common with the immunomodulatory functions previously
attributed to CBD where a switch from Th1 to Th2 dominance
was observed in NOD mice.61 It is essential to note, however,
that the levels of CBD found in herbal cannabis are very low so
its relevance to the clinical management of retinopathy remains
unclear at this time.
Cardiovascular complications
Diabetic patients presenting with micro- and macro-vascular
complications reportedly show significant increases in serum
Key messages
There may be 50,000100,000 diabetic patients in the
Conclusions
This review has demonstrated that the evidence relating
cannabis to diabetes is highly complex and of variable quality.
Some evidence is anecdotal, while some is experimental (i.e.
in vitro) and difficult to extrapolate to humans. The issue of
standardisation of the illicit drug harms has been in the spotlight since the publication in The Lancet of development of a
rational scale to assess the harm of drugs of potential misuse63
in which cannabis is ranked at the lower end of the harm
spectrum. With regard to herbal cannabis, the potential risks
and benefits for diabetic patients remain unquantified at the
present time. Cannabinoids appear to affect biochemical pathways associated with diabetes but it is too early to say whether
this will lead to new treatments.
References
1. Hoare J, Flatley J. Drug Misuse Declared: Findings from the 2007/08
British Crime Survey, England and Wales. London: Home Office, 2008.
2. Anonymous. Marijuana. www.a1b2c3.com/drugs/mjgrow9d.htm
(Accessed 20 August 2010)
271
REVIEW
3. Schultes RE, Hofmann A, Rtsch C. The nectar of delight. In: Plants of the
Gods, 2nd edn (Healing Arts Press, Rochester, Vermont, 2001) 92-101.
4. Royal College of Psychiatrists. Cannabis and mental health. www.
rcpsych.ac.uk/mentalhealthinfo/problems/alcoholanddrugs/cannabis.
aspx. (Accessed 20 August 2010)
5. Frank M. The Marijuana Growers Guide. London: Atlantic Books, 1988.
6. Downer EJ, Campbell, VA. Phytocannabinoids, CNS cells and development: A dead issue? Drug Alcohol Rev 2010;29:91-8.
7. Hardwick S, King L. Cannabis Potency Study. London: Home Office,
2008.
8. Medicines and Healthcare Products Regulatory Agency. Sativex
Oromucuscal spray. London: MHRA, 2010.
9. Fong TM, Heymsfield SB. Cannabinoid-1 receptor inverse agonists:
current understanding of mechanism of action and unanswered questions. Int J Obes (Lond) 2009;33:947-55.
10. European Medicines Agency. Acomplia (rimonabant): withdrawal of the
marketing authorization in the European Union. London: EMEA, 2009
11. Diment E, Harris J, Jotangia D et al. Smoking, drinking and drug use
among young people in England in 2008. London: NHS Information
Centre for Health and Social Care, 2009.
12. Hoare J. Drug Misuse Declared: Findings from the 2008/09 British
Crime Survey England and Wales. London: Home Office, 2010.
13. Independent Drug Monitoring Unit. www.idmu.co.uk/cannabis-use-inbritain.htm. (Accessed 20 August 2010).
14. Masso Gonzalez EL, Johansson S, Wallander MA , Garcia Rodriguez LA.
Trends in the prevalence and incidence of diabetes in the UK: 1996
2005. J Epidemiol Community Health 2009;63:332-6.
15. Koopman RJ, Mainous AG III, Diaz VA, Geesey ME. Changes in age at
diagnosis of type 2 diabetes mellitus in the United States, 1988 to
2000. Ann Fam Med 2005;3:60-3.
16. Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational
scale to assess the harm of drugs of potential misuse. Lancet 2007;
369:1047-53.
17. Craig R, Mindell J (eds). Health Survey for England 2006: Volume 1
Cardiovascular Disease and Risk Factors in Adults. London: The NHS
Information Centre for Health and Social Care, 2008.
18. Zinberg N. Drug, Set, and Setting. New Haven: Yale University, 1984.
19. Advisory Committee on the Misuse of Drugs. Cannabis: Classification
and Public Health. 2008. www.homeoffice.gov.uk/publications/drugs/.../
acmd-cannabis-report-2008. (Accessed 20 August 2010).
20. Anonymous. How many people in the US use medical marijuana?
http://medicalmarijuana.procon.org/view.answers.php?questionID=
001199 (Accessed 20 August 2010).
21. National Treatment Agency for Substance Misuse. NTA business plan
201011. London: NTA, 2010.
22. Amos A, Wiltshire S, Bostock Y, Haw S, McNeill A. You cant go without a fag...you need it for your hash: a qualitative exploration of
smoking, cannabis and young people. Addiction 2004;99:77-81.
23. Le Bec PY, Fatsas M, Denis C et al. Cannabis and psychosis: search of
a causal link through a critical and systematic review. Encephale 2009;
35:377-85.
24. McLaren J, Silins E, Hutchinson D et al. Assessing evidence for a causal
link between cannabis and psychosis: A review of cohort studies. Int J
Drug Policy 2010;21:10-19.
25. Hickman M, Vickerman P, Macleod J et al. Cannabis and schizophrenia:
model projections of the impact of the rise in cannabis use on historical
and future trends in schizophrenia in England and Wales. Addiction
2007;102:597-606.
26. Frisher M, Crome I, Martino O, Croft P. Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom
from 1996 to 2005. Schizophr Res 2009 ;113:123-8.
27. Independent Drug Monitoring Unit. Cannabis and Stress Anxiety. http://
www.idmu.co.uk/canstressdepres.htm. (Accessed 20 August 2010).
28. Weiss L, Zeira M, Reich S, et al. Cannabidiol lowers incidence of diabetes in non-obese mice. Autoimmunity 2006;39:143-51.
272
REVIEW
58. Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebocontrolled double-blind clinical trial of cannabis-based medicinal
product (Sativex) in painful diabetic neuropathy: depression is a major
confounding factor. Diabetes Care 2010;33:128-30.
59. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;
376:124-36.
60. Rajesh M, Mukhopadhyay P, Batkai S et al. Cannabidiol attenuates
high glucose-induced endothelial cell inflammatory response
and barrier disruption. Am J Physiol Heart Circ Physiol 2007;293:
H610-9.
61. El-Remessy AB, Al-Shabrawey M, Khalifa Y et al. Neuroprotective and
blood-retinal barrier-preserving effects of cannabidiol in experimental
diabetes. Am J Pathol 2006;168:235-44.
62. Weiss L, Zeira M, Reich S et al. Cannabidiol lowers incidence of diabetes
in non-obese mice. Autoimmunity 2006;39:143-51.
63. Mahdy RA, Nada WM, Hadhoud KM, El-Tarhony SA. The role of vascular endothelial growth factor in the progression of diabetic vascular
complications. Eye (Lond) 2010 May 28. [Epub ahead of print].
273